Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opana ER Should Come Off The US Market, FDA Tells Endo

09 Jun 2017

• By Sue Sutter

Related Content

Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

07 Apr 2017

FDA Moves On Endo’s Opana ER Unlikely To Sweep Up Other Opioids

16 Mar 2017

Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant

17 Sep 2012

Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

21 Nov 2011

Opana ER Looking At REMS – Or Worse – After US FDA Panel Weighs Intravenous Abuse Risk

14 Mar 2017

Opana ER: Effort To Expand US Label Might Lead To Withdrawal Due To Abuse Problems

10 Mar 2017

FDA Crushes Endo’s Hopes, Allows Original <em>Opana</em> Generics To Remain On Market

11 May 2013

Related Companies

Endo, Inc.

Genentech, Inc.

Additional Topics

United States Drug Safety Post Market Regulation & Studies Regulation BioPharmaceutical Neurology

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.